en · de · es · pt
aod-9604-notes.peptides6608.com › Data › Mechanism And Regulatory Status — Complete Guide

Mechanism And Regulatory Status — Complete Guide

By Editorial Desk · published 2026-07-11 · last reviewed 2026-07-30 · Data

A practical reference on lipolysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-07-30. Anything still debated is marked as such rather than presented as settled.

Mechanism and Regulatory Status

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Aod-9604 at a glance

PropertyValueNotes
Typical storage temperature-20 °CLyophilized peptide; protect from moisture and light.
Typical analytical methodHPLC and mass spectrometryUsed to confirm identity and estimate purity.
Common synonymsAOD9604; hGH 176-191Naming varies by supplier and publication.
Disulfide bondsOneAffects folded structure and stability.
Typical research purity≥95%Value depends on supplier and analytical method.

Handling, Analysis, and Quality Control

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.

Related pages on this site

Research and Regulatory Status

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Notes from published material

=== Orthologs === There are currently 193 organisms that are known to be orthologs of EPCIP. The orthologs of EPCIP are deuterostome animals in the clade Chordata. Table 3 shows a range of EPCIP orthologs, their NCBI accession numbers, sequence lengths, and sequence identity to the EPCIP human protein. At this time, EPCIP is not known to have any protostome or invertebrate orthologs.

=== Fentanyl analogs === Fentanyl analogs are types of fentanyl with various chemical modifications on any number of positions of the molecule, but still maintain, or even exceed, its pharmacological effects. Many fentanyl analogs are termed "designer drugs" because they are synthesized solely to be used illicitly. Carfentanil, a fentanyl analog, has an additional methyl ester group attached to the 4 position. Carfentanil is 20–30 times as potent as fentanyl and is common in the illicit drug chain. The drug is commonly used to tranquilize elephants and other large animals.

== Overview == The Montebello High School mascot is known as Ollie the Oiler, and the school's students and alumni are referred to as Oilers, (a reference to when Montebello was an oil-drilling town during the 1920s and 1930s).

Sources: en.wikipedia.org

Further detail

=== Quiboloy's arrest order and Duterte as KOJC administrator === On March 9, 2024, Duterte's longtime friend and Kingdom of Jesus Christ leader, Pastor Apollo Quiboloy, was ordered arrested by the United States Federal Bureau of Investigation after his conviction by a US District Court for alleged cases of sex trafficking, rape, fraud, and cash smuggling. No extradition request was received by the Marcos administration for Quiboloy's arrest, although a probe in the Senate was previously initiated on January 23 by Senator Risa Hontiveros, who invited Quiboloy to attend the hearings. Quiboloy demanded a fair trial as a requirement to attend, though this was rebuked by Hontiveros and Marcos. Claiming his life was under threat through what he described as a connivance between Marcos and the US government, Quiboloy went into hiding and designated Duterte as administrator of his ministry's properties. After Quiboloy refused to attend the hearings, Hontiveros cited him in contempt and recommended the Senate President to order his arrest. Arrest orders for Quiboloy were issued by the Pasig Regional Trial Court despite the efforts of Senators Robin Padilla, Cynthia Villar, and Bong Go to oppose the move. Four separate raids were eventually held in Quiboloy's properties in Davao City; though Quiboloy was not found, the raids were criticized by Duterte and his allies for its "excessive [and] unnecessary force" involving several units of police and military personnel "in full battle gear". KOJC members gathered in a rally in Liwasang Bonifacio calling for justice for Quiboloy.

=== AP Care Homes === Pickston is the Director of AP Care Homes, a company based in the North West of England which provided residential care for children. The home catered for the needs of children aged 12-16 with emotional and behavioural difficulties. It was a long term solution for vulnerable children. It employed a registered manager, deputy manager and seven full time key workers. Following an inspection on 16 and 17 November 2023, Ofsted concluded AP Care Homes Limited had "serious and/or widespread failures that mean children and young people are not protected or their welfare is not promoted or safeguarded and the care and experiences of children and young people are poor and they are not making progress". Ofsted inspectors said that Pickston had overseen the management of the home but "did not have the skills and experience" to run it in line with children's home regulations. It was also found that Pickston took one child to her home and, after an internal investigation found that “professional boundaries had been blurred”, she allegedly offered to do it again three weeks later. The home closed in December 2023 after Ofsted issued a notice suspending the registration of the home.

Erbium(III) oxide (also known as erbia) is the only known oxide of erbium, first isolated by Carl Gustaf Mosander in 1843, and first obtained in pure form in 1905 by Georges Urbain and Charles James. It has a cubic structure resembling the bixbyite motif. The Er3+ centers are octahedral. The formation of erbium oxide is accomplished by burning erbium metal, erbium oxalate or other oxyacid salts of erbium. Erbium oxide is insoluble in water and slightly soluble in heated mineral acids. The pink-colored compound is used as a phosphor activator and to produce infrared-absorbing glass.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for weight loss?

No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.

Why is AOD-9604 banned in sports?

The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.

Does AOD-9604 raise growth hormone levels?

It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.

What is AOD-9604?

It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.

Network